EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI)

Kenta Misaki, Eiichi Tanaka, Eisuke Inoue, Naoto Tamura, Fuminori Hirano, Yoshinori Taniguchi, Hiroshi Sato, Taio Naniwa, Hideto Oshikawa, Tamami Yoshitama, Yuya Takakubo, Yoko Suzuki und 5 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae043 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Kenta Misaki und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan. Hauptthemen laut MEDLINE: Abatacept, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We investigated the long-term effectiveness, safety, and factors affecting Japanese Health Assessment Questionnaire (J-HAQ) improvement during abatacept treatment in Japanese rheumatoid arthritis (RA) patients.

Methods

The Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study is an ongoing observational study of biologic-naïve RA patients with moderate disease activity treated with subcutaneous abatacept (125 mg, once weekly). Patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) were extracted from the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) registry as a historical, weighted control group. The primary end point for this interim analysis was the proportion of patients with J-HAQ remission (score ≤0.5) at 3 years.

Results

Among 279 abatacept-treated and 220 csDMARD-treated patients, J-HAQ remission was achieved at 3 years in 40.5% [95% confidence interval (CI) 34.7–46.2%] and 28.9% (95% CI 9.9–47.8%), respectively. Age, RA duration <1 year, baseline J-HAQ score, and Simplified Disease Activity Index remission at 6 months were associated with 3-year J-HAQ remission in the abatacept group. Overall, 24/298 patients (8.1%; safety analysis set) experienced serious adverse drug reactions with an incidence of 5.3 per 100 person-years.

Conclusions

This study confirmed the 3-year effectiveness and safety and revealed potential factors associated with J-HAQ remission in biologic-naïve RA patients treated with abatacept in real-world clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptArthritis, RheumatoidAntirheumatic AgentsHumansMaleFemaleMiddle AgedJapanAgedTreatment OutcomeSurveys and QuestionnairesAdultRegistriesRemission InductionSeverity of Illness IndexEast Asian People

Stichwörter der Autor:innen

AbataceptJ-HAQlong-termquality of liferheumatoid arthritis

Substanzen

AbataceptAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
  • Showa University Research Administration Center, Showa University, Tokyo, Japan.
  • Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
  • Department of Rheumatology, NHO Asahikawa Medical Center, Hokkaido, Japan.
  • Department of Rheumatology, Bayside Misato Medical Center, Kochi, Japan.

Zitieren

APA

Misaki, K., Tanaka, E., Inoue, E., Tamura, N., Hirano, F., Taniguchi, Y., Sato, H., Naniwa, T., Oshikawa, H., Yoshitama, T., Takakubo, Y., Suzuki, Y., Himeno, S., Tsuritani, K., Matsumoto, S., Yamanaka, H., & Harigai, M. (2024). Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI). Modern Rheumatology. https://doi.org/10.1093/mr/roae043

Vancouver

Misaki K, Tanaka E, Inoue E, Tamura N, Hirano F, Taniguchi Y, et al. Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI). Modern Rheumatology. 2024. doi:10.1093/mr/roae043

BibTeX
@article{Misaki2024,
  author = {Misaki, Kenta and Tanaka, Eiichi and Inoue, Eisuke and Tamura, Naoto and Hirano, Fuminori and Taniguchi, Yoshinori and Sato, Hiroshi and Naniwa, Taio and Oshikawa, Hideto and Yoshitama, Tamami and Takakubo, Yuya and Suzuki, Yoko and Himeno, Shinkichi and Tsuritani, Katsuki and Matsumoto, Shigeru and Yamanaka, Hisashi and Harigai, Masayoshi},
  title = {Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI)},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae043}
}
Kostenlos starten →